Quick Reference Chart

Roflumilast

Zoryve® (Cream)

QD

0.3% (≥6 yrs of age)

Does not specify

PDE-4 inhibitor
(reduction in multiple
pro-inflammatory
cytokines)

May be used on any skin site, for any severity of disease; no limitation on duration of use; no warnings or precautions in package insert**; PI specifically mentions indication for
intertriginous areas. The 0.3% foam formulation is FDA approved for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

Calcipotriene

Dovonex® (Ointment,
Cream), Sorilux®
(Foam)

QD to BID

0.005% Sorilux® (≥4 yrs of age) Dovonex® (≥18 yrs age)

<100g per week

Vitamin D analogue;
Anti-inflammatory,
Anti-proliferative

Used as monotherapy or adjunctively with topical corticosteroids for steroid-sparing effects. Use with caution with prolonged and widespread use in patients with significant hypercalcemia.

Tazarotene

Tazorac® (Gel, Cream)

QD

0.05%, 0.1% (≥18 yrs of age)

Does not specify

Retinoid;
Anti-inflammatory,
Anti-proliferative

May be used as monotherapy or adjunctively with topical corticosteroids for steroid-sparing effects; gel vehicle with greater risk of skin irritation especially with monotherapy; contraindicated in pregnancy; causes photosensitivity.

Calcipotriene and Betamethasone Dipropionate

Enstilar® (Foam),
Taclonex® (Ointment,
Suspension), Wynzora®
(Cream)*

QD

0.005/0.064% Enstilar® (≥12 yrs of age) Wynzora® (≥18 yrs of age) Taclonex® (≥12 yrs of age)

<60 g q4 days (Enstilar®) <100 g per week in adults <60 g per week in 12-17 yr old patients (Taclonex®/Wynzora®)

Vitamin D analogue &
corticosteroid combo;
Anti-inflammatory,
Anti-proliferative

Usual warnings with topical corticosteroids/ Vitamin D Analogues regarding sites of application, potential local adverse effects, prolonged durations of use, and potential systemic adverse effects apply

Halobetasol Propionate and Tazarotene

Duobrii® (Lotion)

QD

0.01%/0.045% (≥18 yrs of age)

<50 g per week

Retinoid & corticosteroid combo;
Anti-inflammatory,
Anti-proliferative

Formulation allows for lower concentrations of active ingredients without sacrificing efficacy; Usual warnings with topical corticosteroids/retinoids regarding sites of application, potential local adverse effects, prolonged durations of use, and potential systemic adverse effects apply.

Roflumilast

Zoryve® (Cream)

QD

0.15% (≥6 yrs of age)

Does not specify

PDE-4 inhibitor (reduction in multiple pro-inflammatory cytokines)

May be used on any skin site for mild to moderate atopic dermatitis; no limitation on duration of use; no warnings or precautions in package insert**; the 0.3% foam formulation is FDA approved for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older

Ruxolitinib

Opzelura®†
(Cream)

BID

1.5% (≥12 yrs of age)

<60 g per week or
<100 g per 2 weeks;
<20% BSA

JAK 1/2 inhibitor

Efficacy comparable or better than topical triamcinolone in phase 2 study; Rapid and marked reductions in pruritus within hours to days; May be used on any anatomic skin site; boxed warnings noted in label.

Crisaborole

Eucrisa® (Ointment)

BID (can be reduced to QD once control achieved)

2% (≥3 months old)

Does not specify

PDE-4 inhibitor

Continued use limited in some patients by stinging and burning at sites of application (more often observed in real-world than noted in pivotal trials with AD).

Pimecrolimus, Tacrolimus

Elidel® (Cream),
Protopic® (Ointment)

QD to BID

1% cream (≥2 yrs of age),
0.03% and 0.01% ointment (Adults),
0.03% ointment (Children 2-15 yrs of
age)

Does not specify

Calcineurin inhibitor (inhibition of inflammatory cascade)

May be used on any affected anatomic site; some cases limited by local skin irritation; boxed warnings in package insert for malignancy (both agents); approvals designated for second line topical use.